ES2062514T3 - Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento. - Google Patents

Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento.

Info

Publication number
ES2062514T3
ES2062514T3 ES90904258T ES90904258T ES2062514T3 ES 2062514 T3 ES2062514 T3 ES 2062514T3 ES 90904258 T ES90904258 T ES 90904258T ES 90904258 T ES90904258 T ES 90904258T ES 2062514 T3 ES2062514 T3 ES 2062514T3
Authority
ES
Spain
Prior art keywords
amino acid
negatively charged
protein
system including
charged amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90904258T
Other languages
English (en)
Other versions
ES2062514T5 (es
Inventor
Soren Bjorn
Kjeld Norris
Fanny Norris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2062514(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK494189A external-priority patent/DK494189D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of ES2062514T3 publication Critical patent/ES2062514T3/es
Application granted granted Critical
Publication of ES2062514T5 publication Critical patent/ES2062514T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Processing Of Solid Wastes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Particle Accelerators (AREA)

Abstract

UN POLIPEPTIDO PARA LA PRODUCCION DE LEVADURA COMPRENDE LA FUSION DEL PEPTIDO DE SEÑAL, UN PEPTIDO LIDER Y UNA PROTEINA HETEROLOGUS O UN POLIPEPTIDO. EL POLIPEPTIDO ES MODIFICADO DE SU SECUENCIA AMINOACIDA EN UN LUGAR PROXIMO AL PROCESO, LOCALIZADO EN EL EXTREMO DE LA C-TERMINAL DEL PEPTIDO LIDER Y EN EL EXTREMO N-TERMINAL DE LA PROTEINA HETEROLOGUS, PARA SUMINISTRAR UNA PRESENTACION DEL LUGAR DE PROCESO QUE LO HACE ACCESIBLE A LA RUPTURA PEOTEOLITICA. DICHA PRESENTACION SE SUMINISTRA AÑADIENDO UNO O MAS AMINOACIDOS (AL MENOS UNO QUE ESTA CARGADO NEGATIVAMENTE) A CUALQUIER EXTREMO C-TERMINAL DEL LIDER O AL EXTREMO N-TERMINAL DE LA PROTEINA, O AMBOS. LA PROTEINA HETEROLOGUS PUEDE, POR SUPUESTO, SER UN PRECURSOR OPROTININ O INSULINA O UN ANALOGO DE ELLOS.
ES90904258T 1989-03-03 1990-03-01 Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento. Expired - Lifetime ES2062514T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK105489A DK105489D0 (da) 1989-03-03 1989-03-03 Polypeptid
DK494189A DK494189D0 (da) 1989-10-06 1989-10-06 Polypeptid

Publications (2)

Publication Number Publication Date
ES2062514T3 true ES2062514T3 (es) 1994-12-16
ES2062514T5 ES2062514T5 (es) 1998-06-01

Family

ID=26065137

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90904258T Expired - Lifetime ES2062514T5 (es) 1989-03-03 1990-03-01 Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento.

Country Status (23)

Country Link
US (3) US5395922A (es)
EP (1) EP0461165B2 (es)
JP (1) JP2609367B2 (es)
KR (1) KR970005928B1 (es)
AT (1) ATE110414T1 (es)
AU (1) AU624694B2 (es)
CA (1) CA2050336C (es)
CZ (1) CZ285239B6 (es)
DD (1) DD296965A5 (es)
DE (1) DE69011853T3 (es)
DK (2) DK105489D0 (es)
ES (1) ES2062514T5 (es)
FI (1) FI104985B (es)
HU (2) HU215538B (es)
IE (1) IE66469B1 (es)
IL (1) IL93609A (es)
NO (2) NO304236B1 (es)
NZ (1) NZ232742A (es)
PL (1) PL163532B1 (es)
RU (1) RU2194758C2 (es)
UA (1) UA27706C2 (es)
WO (1) WO1990010075A1 (es)
ZA (1) ZA901476B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
CA2057908A1 (en) * 1989-05-19 1990-11-20 John E. Cronan, Jr. Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
GB9015825D0 (en) * 1990-07-18 1990-09-05 Ciba Geigy Ag In vitro processing of fusion proteins
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
IL114160A (en) * 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
DE19629982A1 (de) 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
WO1998026080A1 (en) 1996-12-13 1998-06-18 Chiron Corporation Method for expression of heterologous proteins in yeast
ES2258797T3 (es) * 1996-12-20 2006-09-01 Novo Nordisk A/S Proteinas con extension n-terminal expresadas en la levadura.
JP2001527387A (ja) * 1997-01-24 2001-12-25 ノボ ノルディスク アクティーゼルスカブ 合成リーダーペプチド配列
US6046000A (en) * 1997-11-07 2000-04-04 Millennium Biotherapeutics, Inc. Method for identifying genes encoding signal sequences
WO1999037793A1 (en) 1998-01-23 1999-07-29 Novo Nordisk A/S Process for making desired polypeptides in yeast
CA2392844A1 (en) 1999-12-29 2001-07-12 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP1274720A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
DE60335497D1 (de) 2002-09-13 2011-02-03 Cornell Res Foundation Inc Ergillus-phytasen
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
CN102660614A (zh) 2005-08-16 2012-09-12 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー／エス 新規インシュリン誘導体
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
US20080026376A1 (en) * 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
US8518668B2 (en) 2006-09-27 2013-08-27 Novo Nordisk A/S Method for making maturated insulin polypeptides in a fungal cell
US8153395B2 (en) 2006-11-22 2012-04-10 Novo Nordisk A/S Method of making activated carboxypeptidases
US20100216691A1 (en) 2007-07-16 2010-08-26 Novo Nordisk A/S Protease Stabilized, Pegylated Insulin Analogues
CN101778862B (zh) 2007-08-13 2014-12-17 诺沃-诺迪斯克有限公司 快速作用的胰岛素类似物
ES2548304T3 (es) 2007-08-15 2015-10-15 Novo Nordisk A/S Análogos de la insulina que contienen una fracción acilo y alquilenglicol
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
US9242011B2 (en) 2008-04-01 2016-01-26 Novo Nordisk A/S Insulin albumin conjugates
WO2011089170A2 (en) 2010-01-22 2011-07-28 Novo Nordisk A/S Process for preparing fgf-21 with low degree of o-glycosylation
KR101702342B1 (ko) * 2009-03-12 2017-02-03 빅텍 프라이빗 리미티드 폴리뉴클레오타이드 및 폴리펩타이드 서열 및 이의 방법
PT2612677E (pt) 2009-06-26 2015-09-10 Novo Nordisk As Preparação compreendendo insulina, nicotinamida e arginina
EP2504355B1 (en) 2009-11-25 2015-07-22 Novo Nordisk A/S Method for making polypeptides
KR20130036290A (ko) 2010-06-23 2013-04-11 노보 노르디스크 에이/에스 추가 이황화 결합을 함유하는 인슐린 유도체
WO2011161124A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
WO2011161083A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Human insulin containing additional disulfide bonds
US20130331320A1 (en) 2010-12-14 2013-12-12 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
CA2821613A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
US9260503B2 (en) 2011-06-15 2016-02-16 Novo Nordisk A/S Multi-substituted insulins
RU2460795C1 (ru) * 2011-07-06 2012-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") Способ микробиологического синтеза секретируемого соматотропина человека и штамм дрожжей saccharomyces cerevisiae - продуцент секретируемого соматотропина человека
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
CN103254277B (zh) 2013-05-03 2017-02-08 南京工业大学 强分泌性信号肽增强小肽模序及其应用
US20160115216A1 (en) 2013-06-07 2016-04-28 Novo Nordisk A/S Method for Making Mature Insulin Polypeptides
PL233560B1 (pl) 2014-12-05 2019-10-31 Mabion Spolka Akcyjna Sposób otrzymywania insuliny lub analogu insuliny z prekursora rekombinowanego białka
WO2016144658A1 (en) 2015-03-10 2016-09-15 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
AR106364A1 (es) 2015-08-25 2018-01-10 Novo Nordisk As Derivados de insulina y sus usos médicos
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
KR102043067B1 (ko) * 2017-08-08 2019-11-11 엘지전자 주식회사 차량용 사이드 미러 및 차량
TW201917134A (zh) 2017-08-17 2019-05-01 丹麥商諾佛 儂迪克股份有限公司 新穎的醯基化胰島素類似物及其用途
DK4073097T3 (da) 2019-12-11 2024-08-19 Novo Nordisk As Nye insulinanaloger og anvendelser heraf
WO2023144240A1 (en) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Glucose sensitive insulin derivatives and uses thereof
DE202024104234U1 (de) 2024-07-26 2024-12-18 Australian Geekkit Health Pty Ltd Peptid-Struktur-Partikel mit Signalübertragung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5712580A (en) * 1979-04-05 1980-10-09 James Joseph Connell Engine charging and scavenging
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
WO1984004330A1 (en) * 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
EP0195680A3 (en) * 1985-03-21 1987-06-10 Immunex Corporation The synthesis of protein with an identification peptide
JPS6236183A (ja) * 1985-06-20 1987-02-17 ザ・サルク・インステイチユ−ト・バイオテクノロジ−／インダストリアル・アソシエイツ・インコ−ポレ−テツド サツカロミセス・セレビシエからのポリペプチドの発現および分泌
MC1834A1 (fr) * 1986-07-10 1988-06-03 Transgene Sa Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
FI896261A7 (fi) * 1987-06-24 1989-12-22 Novo Nordisk As Menetelmä proteiinin tai polypeptidin valmistamiseksi, polypeptidiä ko odaava DNA-sekvenssi, DNA-sekvenssin sisältämä mikro-organismi sekä po lypeptidi ja sen käyttö farmaseuttisena valmisteena
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
DK463887D0 (da) * 1987-09-07 1987-09-07 Novo Industri As Gaerleader
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
DK336188D0 (da) * 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
AU633020B2 (en) * 1988-07-23 1993-01-21 Novozymes Delta Limited New secretory leader sequences
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
ATE110414T1 (de) 1994-09-15
HU902376D0 (en) 1991-11-28
DD296965A5 (de) 1991-12-19
CA2050336C (en) 2000-01-18
UA27706C2 (uk) 2000-10-16
NO913427L (no) 1991-11-01
PL163532B1 (pl) 1994-04-29
DE69011853T2 (de) 1994-12-15
JP2609367B2 (ja) 1997-05-14
WO1990010075A1 (en) 1990-09-07
HU215538B (hu) 1999-01-28
NO974899L (no) 1997-10-23
EP0461165B1 (en) 1994-08-24
US5395922A (en) 1995-03-07
FI104985B (fi) 2000-05-15
NZ232742A (en) 1991-10-25
ZA901476B (en) 1990-11-28
DE69011853T3 (de) 1998-06-25
AU624694B2 (en) 1992-06-18
JPH04504846A (ja) 1992-08-27
NO913427D0 (no) 1991-09-02
CZ285239B6 (cs) 1999-06-16
KR970005928B1 (ko) 1997-04-22
RU2194758C2 (ru) 2002-12-20
AU5261290A (en) 1990-09-26
NO304236B1 (no) 1998-11-16
ES2062514T5 (es) 1998-06-01
HUT58370A (en) 1992-02-28
IE66469B1 (en) 1995-12-27
KR920701452A (ko) 1992-08-11
US5510249A (en) 1996-04-23
EP0461165B2 (en) 1998-03-25
US5514585A (en) 1996-05-07
EP0461165A1 (en) 1991-12-18
DK105489D0 (da) 1989-03-03
IE900749L (en) 1990-09-03
CA2050336A1 (en) 1990-09-04
DK0461165T3 (da) 1994-11-21
NO974899D0 (no) 1997-10-23
HU211600A9 (en) 1995-12-28
IL93609A0 (en) 1990-12-23
FI914125A0 (fi) 1991-09-02
IL93609A (en) 2001-11-25
DE69011853D1 (de) 1994-09-29
CZ103990A3 (cs) 1999-03-17

Similar Documents

Publication Publication Date Title
ES2062514T5 (es) Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento.
ES2059547T3 (es) Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado.
ES2124295T3 (es) Expresion y purificacion de factor tisular soluble recombinante.
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
PT99118A (pt) Processo de preparacao de protease de interleucina 1b,de inibidores da protease de interleucina 1b e de composicoes farmaceuticas
ATE139540T1 (de) Heilmittelpeptide
DK521386D0 (da) Fremgangsmaade til bestemmelse af aminosyre-sekvensen af et polypeptid, som er komplementaert til et peptid eller protein eller en del heraf, samt middel til brug ved fremgangsmaaden
BR9713108A (pt) Colagenase recombinante do tipo i de clostridium histolytucum e o uso da mesma para o isolamento de células e de grupos de células
DK66391D0 (da) Terapeutisk virksomme peptider
ES2065907T3 (es) Procedimiento para la produccion de un peptido fisiologicamente activo que contiene un resto cisteina.
Benjannet et al. GAWK, a novel human pituitary polypeptide: isolation, immunocytochemical localization and complete amino acid sequence
EP0210279A4 (en) Stabilized human prourokinase.
PT95016A (pt) Processo para a preparacao de peptidos terapeuticos
ES2091897T3 (es) Procesamiento in vitro de proteinas de fusion.
Anouar et al. Identification of a novel secretogranin II-derived peptide in the adult and fetal human adrenal gland
ES2107525T3 (es) Peptido trombolitico, su produccion y agente trombolitico.
ES2158235T3 (es) Peptidos antigenicos con substituciones de glicina.
BRANDAU et al. New bovine adrenal medullary peptide and its precursor
LUCAS et al. SCORPION Tityus serrulatus LUTZ AND MELLO.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 461165

Country of ref document: ES